Arvinas (ARVN) Cash from Operations Growth (5y) (2022 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Cash from Operations Growth (5y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.38% |
| Mar 31, 2026 | -12.15% |
| Dec 31, 2025 | -0.97% |
| Sep 30, 2025 | -21.43% |
| Jun 30, 2025 | -34.84% |
| Mar 31, 2025 | -39.30% |
| Dec 31, 2024 | -39.10% |
| Sep 30, 2024 | -134.59% |
| Jun 30, 2024 | 41.67% |
| Mar 31, 2024 | -50.25% |
| Dec 31, 2023 | -46.64% |
| Sep 30, 2023 | -50.49% |
| Jun 30, 2023 | -48.76% |
| Mar 31, 2023 | -46.40% |
| Dec 31, 2022 | -35.27% |